Second session of the Longevity Therapeutics summit, held January 29–31 in San Francisco, CA.
Live coverage of the morning session of Longevity Therapeutics 2019: “Enhancing & Accelerating Aging Research & The Development of Therapies Targeting Age-Related Diseases”.
Longevity science presents novel financial, development, regulatory, and clinical challenges to biotechnology/pharmaceutical entrepreneurs. Using one company as an exemplar, this workshop you will explored the fundamentals of launching and growing a successful biotechnology/ pharmaceutical business, with an emphasis on nuances specific to the emerging anti-aging industry.
The centerpiece of the event was a panel discussion among five luminaries of the aging field:
Laura Deming, founder of Longevity Fund and Age1
Simon Melov, professor at the Buck Institute for Research on Aging
Aydin Senkut, founder and managing partner of Felicis Ventures
Kristen Fortney, founder and CEO of BIOAGE
Sonia Arrison (moderator), author of “100 Plus: How the Coming Age of Longevity Will Change Everything”
A first-in-human trial showed that dasatinib+quercetin (DQ), a drug cocktail that targets senescent cells, has beneficial effects in patients with idiopathic pulmonary fibrosis (IPF), a devastating lung disease associated with aging.
RNA sequencing data from human skin cells can be used to predict the donor’s age, bringing us closer to having an accurate, relatively noninvasive biomarker of aging that can be used in longitudinal and population studies.
A new approach using DNA methylation patterns is capable of predicting chronological age more accurately than any previously published model.
Part 2 of a series of articles covering Unity Biotechnology’s inaugural R&D Day, a special presentation to investors and analysts highlighting the company’s recent progress and future plans.
Detailed summaries of Unity Biotechnology’s investor & analyst event, held Dec. 11, 2018.
Fisetin, a natural compound found in berries and other fruits and vegetables, kills senescent cells and extends lifespan in mice.
Bioinformaticians at Mount Sinai analyzed electronic medical record (EMR) data from more than 300,000 patients. Using an AI technique known as deep learning, they could predict a subject’s chronological age from their medical history.
Two widely used antibiotics can kill senescent cells in vitro, illustrating the potential power of drug repurposing approaches to identify approved compounds with novel anti-aging activities.
Live blogging of BAAM. Check back for updates!
The inaugural Longevity Therapeutics Summit, a conference devoted to transforming the latest developments in aging research into therapies targeting age-related diseases, will be held January 29–31, 2019, in San Francisco.